News & Updates

Show Multimedia Only
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
22 May 2026 byDr. Fernando Martinez, Weil Cornell Medical Center, New York City, New York, US; Dr. Richard Shek-Kwan Chang, Associate Consultant, Division of Neurology, Department of Medicine, Queen Mary Hospital, Hong Kong; รศ. พญ.ชุตินธร ศรีพระประแดง; Dr. Test John Doe, Doctor, Test University of Filipiñas; Dr. Margarita Sánchez del Rio, Clínica Universidad de Navarra, Madrid, Spain; Dr. Christina Man-Tung Cheung, Resident in Dermatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong; Lee Chin Peng, MBBS, FRCOG, FHKAM(O&G); Stephen Padilla; Professor John Colombo; Suresh Kini, MD, MRCOG

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Dupilumab eases itch, disease activity in chronic spontaneous urticaria
22 May 2026
Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs
Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs
13 May 2026 byKanas Chan

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.

Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs
13 May 2026
‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer
‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer
17 Mar 2026

Survival and clinical [Disease Link 9] outcomes in patients with advanced stage [Disease Link 10] endometrial cancer are [Disease Link 11] comparable among the different sequences of adjuvant chemotherapy and radiation therapy, a recent study has shown. However, “sandwich” therapy results in less chronic toxicity, which provides an opportunity for a better quality of life in survivorship.

‘Sandwich’ sequencing of adjuvant chemoradiation tied to less toxicity in advanced endometrial cancer
17 Mar 2026